Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Health advocacy groups back H.1092 to tie drug prices to value; industry and some patient groups warn of overreach
Summary
Health Care For All, disability advocates and students urged the Joint Committee to advance H.1092, which would authorize CHIA and the Health Policy Commission to review the clinical value of high-priced drugs and publish proposed values.
BOSTON — Supporters of House Bill 1092 told the Joint Committee on Financial Services the state needs new tools to evaluate whether high-priced medicines deliver commensurate clinical benefit and to hold manufacturers accountable for excessive prices.
Grace Jurkovich, policy manager at Health Care For All, testified that prescription drug spending is the fastest-growing category of health care cost and that H.1092 would allow the Center for Health Information and Analysis (CHIA) to refer high-cost drugs to the Health Policy Commission (HPC) for further review and possible publication of a proposed value. "These provisions are important because often…
Already have an account? Log in
Subscribe to keep reading
Unlock the rest of this article — and every article on Citizen Portal.
- Unlimited articles
- AI-powered breakdowns of topics, speakers, decisions, and budgets
- Instant alerts when your location has a new meeting
- Follow topics and more locations
- 1,000 AI Insights / month, plus AI Chat
